Sat, Feb 28, 2015, 3:03 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • godwinpeak godwinpeak Sep 12, 2013 5:49 PM Flag

    Enthusiasm for an AFFY Long Position

    AFFY at $1.50 per share suggests that AFFY longs are quite optimistic that O is returning to market very soon both to the US and worldwide. Moreover, AFFY longs agree Takeda milestone/royalties are going to be in the hundreds of millions of dollars . What indicia/evidence can AFFY longs identify to justify their optimism? I cannot say. I have not seen any other than AFFY long "Say So" or blue sky cheer leading.

    Here are verifiable/valid reasons I do not share the AFFY longs' optimism:

    -O's PEARL study proved O was unsafe for CKD patients not on dialysis.
    - Takeda long ago decided not to market O in Japan.
    - Takeda withdrew O's EMA MAA. At the time it withdrew it, the EMA was of the provisional opinion that O would not have been approved because its benefits did not outweigh its risks.
    - Fresenius CC suggests Takeda still does not know the root cause of O's safety problems, and will not find out anytime soon.
    -Takeda does not project any O revenue for its FY 2013 or beyond.
    -Takeda has not issued any press to verify its intent to return O to market, or to project any time frame to do so.
    -All manufacturing contracts for O have been terminated, and O's manufacture takes long lead times.
    - Takeda removed O as one of its core products on its website.
    -Takeda shut down O's own website.
    -O has a limited market - just CKD patients on dialysis.
    -O has a damaged reputation due to negative perceptions about O's patient safety.
    -O has plenty of competition from FDA approved ESAs for CKD patients generally [not just those on dialysis] with many years of use and proven patient safety profiles: [Epogen/Aranesp/Procrit]
    -O's once a month convenience factor (lost on CKD dialysis patients infused 3x week) will be even more seriously undermined when Roche's Mircera, dosed once every 3 to 4 weeks, enters the US market in mid2014.
    -The major dialysis centers, Fresenius and DaVita, have signed multi-year contracts for Amgen's ESAs.
    -AFFY insiders are selling.
    -TBG warns AFFY may go BK

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.1501+0.0001(+0.07%)Feb 27 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.